LUNESTA: New prescription, non-narcotic sleep aid

[Guest guest]

LUNESTA™ Now Widely Available by Prescription to Treat Insomnia;

Estimated 100 Million Americans Suffer From Insomnia

MARLBOROUGH, Mass., April 7 /PRNewswire-FirstCall/ -- Sepracor Inc.

today announced that LUNESTA (eszopiclone 1 mg, 2 mg and 3 mg

tablets) is now available by prescription in most pharmacies nationwide.

LUNESTA is the first and only sleep aid (prescription or over-the-counter),

which has been approved by the U.S. Food and Drug Administration (FDA) for

long-term treatment of insomnia. LUNESTA is the first treatment in its class

that has been shown to not only help patients fall asleep quickly, but also

sleep all through the night.

" LUNESTA is a new prescription, non-narcotic sleep aid approved to treat

insomnia and, unlike other sleep aids, is approved for long-term use, " said

Winkelman, M.D., Ph.D., Associate Director for the Sleep Disorders

Program at Brigham and Women's Hospital, Boston. " LUNESTA is an

important treatment option for the millions of people who have the ongoing

problem of not getting a good night's sleep. "

LUNESTA is approved as a prescription, non-narcotic sleep aid to treat

insomnia. Insomnia symptoms can include difficulty falling asleep and/or not

sleeping all through the night. LUNESTA has been studied in patients for up

to 12 months and in more than 30 clinical trials enrolling more than 4,700

patients.

" I am extremely pleased that millions of patients who have trouble sleeping,

whether it be on a short- or long-term basis, have an effective new

prescription treatment option available in their local pharmacy, " continued

Winkelman. " I expect that LUNESTA, with its approval for long-term use and

effectiveness in helping people stay asleep through the night, will allow most

people who suffer from insomnia to get a refreshing night of sleep without

feeling groggy the next day. "

About Insomnia

Insomnia can include difficulty falling asleep as well as difficulty maintaining

sleep through the night. An estimated 100 million adult Americans suffer from

either chronic or occasional insomnia.(1) Symptoms of insomnia include

difficulty falling asleep, awakening frequently during the night, waking up too

early, an inability to fall back to sleep, or awakening feeling unrefreshed.

Insomnia can be a serious condition. If left untreated, it may become

progressively worse and in turn, potentially affect a person's emotional,

mental and physical health.

Important Safety Information

LUNESTA should only be taken immediately before bedtime. Be sure you

have at least eight hours to devote to sleep before becoming active. You

should not engage in any activity after taking LUNESTA that requires

complete alertness, such as driving a car or operating machinery. You should

use extreme care when engaging in these activities the morning after taking

LUNESTA. Do not use alcohol while taking any sleep medicine. All sleep

medicines carry some risk of dependency. Do not use sleep medicines for

extended periods without first talking to your doctor. Side effects may include

unpleasant taste, headache, drowsiness and dizziness.

Please visit http://www.sepracor.com/ or http://www.lunesta.com/ to access the

FDA-approved labeling text for LUNESTA.

About Sepracor

Sepracor Inc. is a research-based pharmaceutical company dedicated to

treating and preventing human disease through the discovery, development

and commercialization of innovative pharmaceutical products that are

directed toward serving unmet medical needs. Sepracor's drug development

program has yielded an extensive portfolio of pharmaceutical compound

candidates with a focus on respiratory and central nervous system disorders.

The company's commercialization efforts are carried out by its U.S.-based,

1,250-person, primary care and specialty-oriented sales force. Sepracor's

corporate headquarters are located in Marlborough, Massachusetts.

This news release contains forward-looking statements that involve risks and

uncertainties, including statements with respect to the availability and

commercial launch of LUNESTA brand eszopiclone, as well as the safety,

efficacy and potential benefits of LUNESTA. Among the factors that could

cause actual results to differ materially from those indicated by such forward-

looking statements are: unexpected interruptions in commercial distribution of

LUNESTA; Sepracor's ability to fund, and the results of, further clinical

trials;

the timing and success of submission, acceptance and approval of additional

regulatory filings; the scope of Sepracor's patents and the patents of others;

the commercial success of LUNESTA; the ability of the company to attract and

retain qualified personnel; and certain other factors that are detailed in the

company's annual report on Form 10-K for the year ended December 31,

2004 filed with the Securities and Exchange Commission.

In addition, the statements in this press release represent Sepracor's

expectations and beliefs as of the date of this press release. Sepracor

anticipates that subsequent events and developments may cause these

expectations and beliefs to change. However, while Sepracor may elect to

update these forward-looking statements at some point in the future, it

specifically disclaims any obligation to do so. These forward-looking

statements should not be relied upon as representing Sepracor's

expectations or beliefs as of any date subsequent to the date of this press

release.

LUNESTA is a trademark of Sepracor Inc.

(1) Extrapolated to current population from 2000 census based on Ancoli-

Israel et al. SLEEP. 1999;22 (suppl 2):S347-S353.

CONTACT: P. Southwell, Executive Vice President and Chief Financial

Officer, or Jonae R. , Vice President, Investor Relations, +1-508-481-

6700, both of Sepracor Inc.

Web site: http://www.sepracor.com/